




DRUG DISCOVERY

Lead Optimization Strategies

Future developments, threats and opportunities for big pharma, specialty pharma and biotech

By Dr CL Barton

 Table of Contents

Dr Cheryl L Barton

Dr CL Barton has over 10 year's practical pharmaceutical research experience with a leading pharmaceutical company and Pan-European Pharmaceutical analyst with a European Bank.

Dr CL Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Where applicable the research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and isolate the key drivers within the pharmaceutical sector. For more details visit www.pharmavision.co.uk.

Copyright © 2005 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Lead Optimization Strategies

Executive Summary	10
The importance of lead optimization	10
Traditional big pharma strategies	11
Alternative strategies used by specialty pharma and biotech	12
Future developments in lead optimization	13
Commercial threats and opportunities	14
Chapter 1 The importance of lead optimization	16
Summary	16
Introduction	17
Current issues facing the pharmaceutical industry	18
Introduction to lead optimization	22
Hit generation	23
Lead identification	23
Lead optimization	23
Lead optimization in the R&D process	24
Time and costs associated with lead optimization	25
Commercial and clinical importance of lead optimization	26
Lead optimization strategies	27
Traditional big pharma strategies	28
Alternative strategies used by specialty pharma and biotech	29
Differences in strategy	29
Chapter 2 Traditional big pharma strategies	32
Summary	32
Introduction	33

A typical screening cascade	34
Key strategic components in lead optimization	37
Team organization for lead optimization	37
Medicinal chemistry functionality	38
Sources of hits and leads	40
Proprietary collections	41
Commercial non-exclusive libraries	41
Natural products	42
Academic groups	43
Advantages and disadvantages of hit sources	43
Improving the quality of compound collections	44
Case study 1: AstraZeneca	44
Case study 2: GSK	45
Setting the criteria for hits, leads and candidate drugs	45
Key technologies involved in lead optimization	47
HTS technologies	49
NMR	50
Utility of modeling in lead optimization	52
<i>In silico</i> modeling	53
<i>In vitro</i> modeling	53
Computational chemistry	55
Virtual screening	56
Library design	58
HT protein crystallography	59
Application of molecular biology in lead optimization	61
ADMET screening	62
The role of DMPK in lead optimization	62
Metabolism and covalent binding	63
Toxicity	63
Assays for assessing toxicity	65
HT chemistry	68
Preparative LC-MS chromatography	68
Supercritical Fluid Chromatography (SFC)	68
Outsourcing lead optimization	69
Weaknesses of the traditional lead optimization model	71
Sequential data gathering	71
Single compound synthesis	72
Animal models	73
Conclusions	74

Chapter 3 Alternative strategies used by specialty pharma & biotech 78

Summary	78
Introduction	79

Alternative lead optimization strategies	80
Mimicking big pharma cascades	81
Polypharmacology	82
Short/partial screening cascades	86
Case Study: ArQule	86
Computational approaches	89
Case study: Locus Pharmaceuticals	91
Alternative approaches to screening	93
HT crystallography	97
Nanotechnology	99
Scanning probe microscopy	100
Nanoparticle formulation	101
Outsourcing lead optimization	101
Lessons from specialty pharma/biotech strategies	103
Conclusions	104

Chapter 4 Future developments in lead optimization 108

Summary	108
Introduction	109
Key improvement opportunities	109
Reductions in time	110
<i>In silico</i> models	110
Producing fewer compounds of higher quality more efficiently	111
Cheminformatics	111
Bridging the chemistry and target space gap	112
Miniaturization of chemistry	115
More efficient screening cascades	116
Systems biology	116
Zebrafish model	120
Reducing high attrition rates during lead optimization	121
The ‘omic revolution: transforming drug discovery	121
Technology developments	124
Lead optimization, 2010-2015	126
Conclusions	128

Chapter 5 Commercial threats and opportunities 132

Summary	132
Introduction	133
Threats	133
Opportunities	134
Commercial threats	136
Industry consolidation	136
Increased drug safety requirements	138
Avoidance of untested innovative new technologies	139
Drive towards lower risk “me too” drugs	140
Commercial opportunities	142
The genomic revolution	142
Changes to orphan drug legislation	144
Changes in regulatory guidelines: Biomarkers helping to improve the chance of new drug approvals	146
Combinatorial biomarkers aiding efficiency within the D&D process	148
In- and out-Licensing opportunities to create new revenues streams for all players within the industry	149
Conclusions	152

Chapter 6 Appendix 154

Abbreviations	154
References	156
Index	162

List of Figures

Figure 1.1:	Global pharmaceutical sales and growth rates, 1997-2004	18
Figure 1.2:	The drug discovery process	22
Figure 2.3:	A schematic of a typical screening cascade	35
Figure 2.4:	Team organization within lead optimization	38
Figure 2.5:	Technologies involved in lead optimization	48
Figure 2.6:	Application of lead optimization technologies in drug development	49
Figure 2.7:	Schematic representation of linked-fragment approaches	51
Figure 2.8:	Temporal correlation between action potential duration and the QT interval on the surface electrocardiogram	54
Figure 2.9:	The role of HT protein crystallography in lead optimization	59
Figure 2.10:	A) Antisense-directed mRNA degradation and B) Gene silencing by RNAi	61
Figure 2.11:	The bacterial SOS assay to identify genotoxins with the <i>umu</i> response	65
Figure 3.12:	No economies of scale in pharmaceutical R&D	79
Figure 3.13:	Gleevec (imatinib) kinase activities	83
Figure 3.14:	Screening the receptorome reveals multiple molecular targets implicated in antipsychotic drug actions	85
Figure 3.15:	Product portfolio of ArQule	87
Figure 3.16:	Schematic of the ArQule preparative LC-MS purification system	88
Figure 3.17:	The different methods and tools for virtual screening	89
Figure 3.18:	The Locus Pharmaceuticals technology platform	91
Figure 3.19:	Simulated annealing of the chemical potential of a fragment	92
Figure 3.20:	Chemical structures and affinity fingerprints for met-enkephalin, vs. morphine, and morphine vs. naltrexone	94
Figure 3.21:	A schematic of the TRAP screening process	96
Figure 3.22:	Fragment sets used for virtual library construction	98
Figure 3.23:	Schematic of the technique of scanning probe microscopy	100
Figure 4.24:	Schematic of the high throughput approaches in modern drug discovery	113
Figure 4.25:	A microreactor chip	116
Figure 4.26:	A schematic on the potential impact that systems biology could have on the drug discovery process	118
Figure 4.27:	Zebrafish Embryo	120
Figure 4.28:	The future of lead optimization by 2015	126
Figure 5.29:	Consolidation within the pharma industry, 1990-2005	137
Figure 5.30:	Trends in R&D spend in Europe and the US, 1990-2000	138
Figure 5.31:	Breakdown of portfolio by source of drug for the top 20 pharmaceutical companies, 2004	150

List of Tables

Table 1.1:	CDER approval times for priority and standard NMEs and BLAs, 1995-2004	19
Table 1.2:	Sales from leading pharmaceuticals companies, 2003-2004	21
Table 1.3:	R&D spend on drug development, 2003	26
Table 1.4:	Constant dollar reduction in total cost per new drug, 2002	27
Table 2.5:	Top 20 pharmaceutical drugs based on 2004 sales (\$bn)	42
Table 2.6:	Lipinski's rule of 5	43
Table 2.7:	Milestone criteria for hits and leads at AstraZeneca	46
Table 3.8:	Efficiency of Locus Pharmaceuticals computational technology	93
Table 3.9:	Leading CROs for lead optimization outsourcing	102
Table 4.10:	Impact of systems biology on drug discovery and development costs	119
Table 4.11:	Utilization and expenditures for key drugs metabolized by CYP2D6, 2003	123
Table 4.12:	Potential cost savings of improvements in lead optimization timescale by 2015	127
Table 5.13:	Commercial threats and opportunities for lead optimization	133
Table 5.14:	Drug withdrawals, 1997-2005	139